HHS agrees to review mifepristone safety based on anti-abortion white papers
The most common form of abortion in the U.S.—a two-pill regimen approved over two decades ago—is now under fresh scrutiny. Prompted by white papers backed by anti-abortion groups, the Trump administration has ordered a review of the safety of medication abortion, despite overwhelming peer-reviewed evidence supporting its safety. Critics call the move politically motivated, based on flawed data and undisclosed sources. With access to reproductive care already limited in much of the country, this FDA review could redefine the national landscape of abortion rights—without new science to justify it. National reporter Sofia Resnick has the full story shared with the North Dakota Monitor.
MinotVoice
MinotVoice authorship is an amalgamation of source material and local context. It is created with a human touch and an occasional AI assist. When licensing allows or content is provided as a news release, that content is also published under MinotVoice authorship and properly attributed within the article.
Subscribe!
It's free and it helps us grow and provide better information ForMinot!
Comments
Register or log in to join the conversation.